The Next Generation in Cancer Diagnostics.

The Next Generation in Cancer Diagnostics.

OncoTarget was created specifically for cancer patients. Every patient s cancer is unique, which is why discovering what makes it unique can be essential for determining how best to treat them. Biomarkers give us insight into exactly why a cancer is taking a certain path. They can also predict how a cancer will respond to a specific therapy. By identifying these genetic mutations, we can determine which targeted therapies or immunotherapies have the best chance of treating a specific cancer, making this an essential tool for creating better treatment plans. OncoTarget - 88 is changing the way cancer is being treated. This highly-sensitive, NGS-based testing series examines the full exons of 88 well-characterized cancer genes found in solid tumors for point mutations, copy number alterations, microsatellite instability (MSI), and rearrangements. OncoTarget - 88 provides oncologists with clinically actionable data including a complete list of all identifiable genetic alterations, relevant FDA-approved drugs and current clinical trials specific to a patient s cancer. The genes tested in OncoTarget - 88 are of highly clinical and biologic importance and are screened using NGS at extremely high coverage. Figure 1. OncoTarget - 88 Components OncoTarget - 48 is a smaller NGS panel created to detect actionable hotspot mutations in the 48 cancer genes most relevant to targeted therapies. With the OncoTarget series, you ll get results that are right on target -- comprehensive, actionable data that will lead to better treatment options for your patients. Table 1. Genes Evaluated in OncoTarget - 88 Analysis Type Sequence analyses for 76 well-characterized cancer genes Copy number analysis for 13 well-characterized cancer genes Rearrangement analysis for 14 well-characterized cancer genes Microsatellite instability analysis for 5 markers ABL1 DDR2 FGFR1 JAK3 NPM1 ROS1 AKT1 EGFR FGFR2 KDR NRAS SMAD4 ALK ERBB2 FGFR3 KIT NTRK1 SMARCB1 APC ERBB4 FLT3 KRAS PALB2 SMO ATM BRAF EZH2 FOXL2 MET PDGFRA SRC Genes Evaluated FANCA GNA11 MLH1 PDGFRB STK11 ALK EGFR ERBB2 ERBB3 FGFR1 FGFR2 FGFR3 KIT MET MYC MYCN PDGFRA RET ALK BCL2 BCR EGFR ETV1 ETV4 ETV6 EWSR1 MLL PDGFRA PDGFRB RARA ROS1 TMPRSS2 BAT-25 BAT-26 MONO-27 NR-21 NR-24 BRCA1 FANCC GNAQ MPL PIK3CA TERT BRCA2 FANCD2 GNAS MSH2 PMS2 BRIP1 FANCE HNF1A MSH6 PTCH1 TSC1 CDH1 FANCF HRAS MTOR PTEN TSC2 CDKN2A FANCG IDH1 NF1 PTPN11 VHL CSF1R FANCL IDH2 NF2 RB1 CTNNB1 FBXW7 JAK2 NOTCH1 RET GoPath Laboratories - 2

OncoTarget Series Table 2. OncoTarget - 88 Key Metrics Regions Analyzed Sequencing Method Bioinformatics Assay Sensitivity >99% Assay Specificity >99% Sequencing Coverage Turn-around Time Sample Requirements Sample Types DNA Input Required Selected regions of 88 genes Illumina next generation sequencing Proprietary analysis methods supplemented by visual inspection 1,000x Average 10-14 days Tumor only or tumor and matched normal* (optimal results) FFPE (Formalin-Fixed Paraffin-Embedded) Tissue Minimum 50 ng *For maximum ability to differentiate somatic mutations from germline mutations, tumor and matched normal samples are recommended. Figure 2. Depiction of Next-Generation Sequencing Data for Identifiying Sequence Alterations Our Proprietary Bioinformatics Algorithm on Targeted Cancer Genes: Analyses performed in a CLIA-certified laboratory designed for high-complexity clinical testing Analysis using validated approach for optimal sensitivity & specificity Detailed inspection and curation of tumor-specific mutations by world-class cancer bioinformatics experts Identification of mutated genes with biologic or clinical implications in human cancer Proprietary Digital Karyotyping analyses for high-resolution annotation of copy number alterations Proprietary PARE translocation analysis algorithms to evaluate tumor-specific rearrangements Proprietary analysis algorithms to evaluate genes and pathways enriched for alterations Proprietary analysis algorithms to identify bona fide sequence changes and to exclude sequence artifacts Proprietary sample preparation methods allow for successful preparation of low abundance, poor quality sample DNA Figure 3. Depiction of NGS Sequencing Data for Identifying Translocations Table 3. Competitor Analysis: OncoTarget - 88 vs. FoundationOne Sensitivity OncoTarget - 88 >99% at 2% mutant allele frequency for base substitutions and indels Turnaround Time (TAT) 10-14 Days 14-17 Days Specificity (With Normal) >99% PPV that mutations called are both present and actually somatic in nature (5% MAF) Use of Patient Normal to Enhance Results Yes No FoundationOne 99% for base substitutions at 5% mutant allele frequency 98% for indels at 10% mutant allele frequency Analysis using patient normal not offered (No normal) GoPath Laboratories - 3

OncoTarget Series Next-Generation Sequencing Method & Workflow Patient samples undergo pathologic evaluations by macroscopic selection of tumor regions, from which DNA is extracted. Next-generation sequencing libraries are constructed from tumor and normal DNA, which are sequenced to 1000x average coverage on Illumina nextgeneration sequencing systems. After base calling and alignment to the human reference genome, the tumor and normal samples are compared to one another to identify tumor-specific sequence mutations, copy number changes, microsatellite instability (MSI) and rearrangements. The data is then compiled into one comprehensive, actionable report. Figure 4. Workflow of Next-Generation Sequencing and Analyses Our Comprehensive Analysis Reporting OncoTarget - 88 gives you a comprehensive, specific look at your patient s cancer and what factors are driving its growth. If a relevant mutation is found, the gene and its specific alteration will be listed on the report, along with the significance of this alteration in relation to your patient s tumor. The OncoTarget TM - 88 report includes: Pathological evaluation of tumor sample Tumor-specific sequence alterations (single base and small index alterations) Therapeutic, predictive, and prognostic information and references regarding mutated genes and pathways with biological or clinical significance Tumor-specific copy number alterations & translocations Description of mutated genes and pathways with biologic or clinical implications Annotation of tumor-specific alteration consequences Data summary statistics (read data and depth distribution across target regions) GoPath Oncotarget88 NGS Panel: Final Report GM16-XXXX GoPath Oncotarget88 NGS Panel: Final Report GM16-5153 GoPath Oncotarget88 NGS Panel: Final Report GM16-5153 DRUG RESPONSE Drugs DISCLAIMERS Associated with Sensitivity for Patient's Tumor Type, Based on Genomic Analysis Date: 10/19/2016 Page: 4 of 4 Order ID: GM16-5153 Page: 3 of 4 Order Date: Date: 09/30/2016 10/19/2016 Order Date: ID: 10/19/2016 GM16-5153 Order ID: Date: GM16-5153 09/30/2016 Order Date: 09/30/2016 Patient Information Specimen Information Physician Information METHOD AND PERFORMANCE Name: XXXXXXX Tissue/Type: Tumor biopsy Referring Physician: xxxxxxxxxxxxx Address: xxxxxxxx Collected: 09/29/2016 Institutionxxxxxxxxxxxxxxxxxxxxx Procedures DOB: Targeted 03/21/1963 cancer gene analysis utilizes a panel Received: for the detection 09/30/2016 of genetic alterations in 88 well-characterized cancer genes. These genes are of Gender: high Male clinical and biologic importance and are screened Specimen/Block using next ID: generation sequencing at extremely high coverage to identify point mutations, Diagnosis: copy number Pancreatic alterations, Cancer microsatellite instability and rearrangements. DNA is prepared from microdissected tumor FFPE or fresh tissue specimens using Qiagen DNA extraction kits. DNA samples were enriched for coding and intronic regions in the genome using custom DNA capture approaches. Enriched DNA was sequenced using massively parallel sequencing instruments. Sequence data were mapped to the reference human genome sequence (hg19) and sequence alterations were determined by comparison of over 250,000 bases of DNA. INTERPRETATION OF RESULTS: Limitations of Approach Next generation sequencing approaches may provide incorrect sequence or mutational data due to insufficient coverage in specific regions of the RESULTS genome, inability to distinguish highly related human sequences, and sequencing errors. The analysis of sequence specific alterations can also be hampered by three aspects related to the sample and DNA. First, the quantity of DNA obtained can be very low, limiting the amount of DNA Genomic molecules Alterations that can Identified: be successfully 4(ALK analyzed mutation, by next mutations, generation KRAS sequencing. mutation) Second, the purity of tumor-derived DNA can be a factor, as a significant portion of the DNA analyzed may be derived from contaminating normal tissues. Third, the mutation allele fraction depends on various Therapies factors including Associated tumor With burden, Potential sample Clinical storage Benefit: time 4 and patient clinical characteristics unrelated to tumor status. It may be used to substantiate the presence or absence of mutations; however, it may not reflect the overall tumor burden. These three aspects can reduce the chance of detecting sequence mutations, amplifications and rearrangements. In addition, this NGS assay is unable to detect large genomic Therapies Deletions Associated of the genes With in the Lack panel. Of Response: 0 Potentially Relevant Clinical Trials: 10 GENES ASSAYED IN GoPath Oncotarget88 Gene Panel Detected Alterations With Potential Therapeutic Implications Gene Transcript ID Alteration Consequence Clinical Significance Therapeutic Implications* ALK CCDS33172.1 p.1429q>r REFERENCES Nonsynonymous Uncertain Significance Potentially relevant clinical trials KRAS CCDS8703.1 p. 12G>D Missense Pathogenic Potentially relevant clinical trials 1. Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, Grody WW, Hegde MR,Hoeltge GA, Leonard DG, Merker JD, Nagarajan R, Palicki LA, Robetorye RS, Schrijver I, Weck KE, Voelkerding KV. College of american pathologists laboratory standards for nextgeneration sequencing clinical tests. Arch Pathol Lab Med. 2015 Apr;139(4):481-93. CCDS11118.1 p.s215mfs*27 Frameshift Pathogenic Potentially relevant clinical trials 2. Simen BB, Yin L, Goswami CP, Davis KO, Bajaj R, Gong JZ, Peiper SC, Johnson ES, Wang ZX. Validation of a next-generationsequencing CCDS11118.1cancer p. 216V>M panel for use in the clinical Missense laboratory. Arch Pathol Lab Med. Pathogenic 2015 Apr;139(4):508-17. Potentially relevant clinical trials 3. Wong SQ, Fellowes A, Doig K, Ellul J, Bosma TJ, Irwin D, Vedururu R, Tan AY,Weiss J, Chan KS, Lucas M, Thomas DM, Dobrovic A, *Therapeutic Parisot Implications: JP, Fox SB. Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective populationbased drug response study of cancer = related patients. to drug sensitivity Br J Cancer. or resistance 2015 Apr as described 14;112(8):1411-20. in Drug Response section of this report; Potentially relevant clinical trials = Associated with gene is related toatrial inthe Clinical Trials section ofthis report. Please note, neither the therapeutic agents nor the trials identified are ranked in order of 4. Chevrier S, Arnould L, Ghiringhelli F, Coudert B, Fumoleau P, Boidot R. Next-generation sequencing analysis of lung and colon potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence of this patient s tumor type. Identification of cancer associated mutations does carcinomas not necessarily reveals indicate a variety good response of genetic toalterations. therapy; while Int absence J Oncol. of2014 acancer Sep;45(3):1167-74. associated mutation does not necessarily indicate poor response to therapy. 5. Clinical Trial Database: https://clinicaltrials.gov/. Drug None Response This assay todrug was developed Associated and validated with Detected by GoPath Laboratories Alteration(s) using Personal Genome Condition Diagnostics Other(PGDx) Relevant CancerSelect T88 Line NGS of Assay. The Source Alterations performance characteristics of this test were determined by GoPath Detected Laboratories. The U.S. Food and Information Drug Administration (FDA) Therapy has not approved or cleared this test; however, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. GoPath Laboratory is authorized under Clinical Laboratory Improvement Amendments (CLIA) and by all states to perform high-complexity testing. GoPath is a College of American Pathologists (CAP) accredited laboratory. Drugs Associated with Sensitivity for Other Tumor Types, Based on Genomic Analysis Drug Response todrug Associated with Detected Alterations SAMPLE REPORT Alteration(s) Detected Condition Other Relevant Information Line of Therapy Electronically Signed By: Jim Lu, MD, PhD Date: 10/19/2016 Page: 1 of 4 GoPath GoPath Pathology Pathology Associates, Associates, 1351 1351 Barclay Barclay Blvd, Blvd, Buffalo Buffalo Grove, Grove, IL 60089 IL 60089 Phone: Phone: (855 (855 ) 467-2849 FAX: ) 467-2849 224-588-9941 FAX: 224-588-9941 GoPath Pathology Associates, 1351 Barclay Blvd, Buffalo Grove, IL 60089 Phone: (855) 467-2849 FAX: 224-588-9941 Source OncoTarget - 48 Hotspot Mutation Analysis We have also created a smaller NGS-based panel that detects hundreds of actionable hotspot mutations in 48 cancer genes most relevant to targeted cancer therapies. OncoTarget - 48 analyzes >35 kilobases (kb) of targeted genomic regions by 212 amplicons in both FFPE and fresh tissues. Validation study on more than 40 samples from common cancer types demonstrated that OncoTarget - 48 is a highly-sensitive, specific, and reproducible NGS assay for the detection of somatic mutations of target cancer genes. The assay provides a high level of uniform coverage across the target genomic regions with >500 average base coverage and >100 minimal base coverage. It has 92% sensitivity and 100% specificity with 91% PPV and 99% NPV for detection of mutations within the genomic sequences covered by the gene panel. Value of limit of detection (LOD) of the assay is 3% for mutation detections. Table 4. Genes Evaluated in OncoTarget - 48 Analysis Type Actionable Hotspot Mutations in 48 Cancer Genes ABL1 ERBB4 JAK2 PIK3CA AKT1 FBXW7 JAK3 PTEN ALK FGFR1 KDR PTPN11 APC FGFR2 KIT RB1 ATM FGFR3 KRAS RET Genes Evaluated BRAF FLT3 MET SMAD4 CDH1 GNA11 MLH1 SMARCB1 CDKN2A GNAQ MPL SMO CSF1R GNAS NOTCH1 SRC CTNNB1 HNF1A NPM1 STK11 EGFR HRAS NRAS ERBB2 IDH1 PDGFRA VHL GoPath Laboratories - 4

OncoTarget Series Providing Suggested Targeted Therapies & Clinical Trials Discovering what mutations are driving a cancer s growth is an essential part of assessing treatment options. Biomarkers can help determine which targeted therapies may or may not be successful in treating a particular type of cancer. Targeted sequencing and mutation analysis obtained from OncoTarget - 88 may include prognostic indicators, improved disease classification, additional therapies and relevant clinical trials. This data can help physicians make treatment recommendations that target a cancer s specific genetic mutation and thus rule out treatment options that are likely to be ineffective. The OncoTarget - 88 report includes a list of FDA-approved drugs and clinical trials that are most relevant to your patient s cancer including somatic vs. germline mutations, microsatellite instability testing, and treatment options based on the patient s specific alterations--information that can be essential for making informed treatment decisions and selecting targeted therapies. Molecular Testing Requisition Solid Tumor Requisition MOLECULAR ONCOLOGY 1351 Barclay Blvd., Buffalo Grove, IL 60089 Tel: 855.467.2849 Fax: 224.588.9941 www.gopathlabs.com PATIENT INFORMATION (Please print) ORDERING PHYSICIAN / LAB INFORMATION (Please print) Name (Last, First) Facility Name Address Name (Last, First) City, State, Zip Address Female Male Date of Birth (M/D/Y) City, State, Zip SSN# (Optional) Phone# Fax# E-Mail: Phone# Ordering Physician (M/D/Y) Diagnosis: NPI#: Treating Physician: Report Delivery: Fax E-Mail Mail Website Only CODING INFORMATION COMMON ICD-10 CODES Diagnosis Code/ICD-10 Code (Required): Bladder: C67 Breast: C50.411, C50.412, C50.419, C50.811, C50.812, C50.819 Brain: C71.9, C79.31 Colon: C18.2, C18.7, C18.9 GIST: C49 Lung: C34.10, The physician is required to document all applicable ICD codes or descriptions for all tests ordered supporting medical necessity which shall be used in patient plan of C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90 care. Example: ICD-10: C73 (Malignant neoplasm of thyroid gland) Melanoma: C43.9 Ovarian: C56 Prostate: C61 Stomach: C16.9 Thyroid: C73 BILLING INFORMATION (Please provide copy of insurance card) SPECIMEN INFORMATION (Please provide copy of pathology report) Primary Insurance: Pathology Department: Bill: Insurance Medicare Medicaid Hospital Client Self Pay Phone#: Secondary Insurance: Yes No If yes, please attach secondary insurance form Specimen Block ID/#: Secondary Insurance: Collection Date (M/D/Y): Place of Service: 21 - Inpatient Hospital 22 - Outpatient Hospital 24 - Ambulatory Surgery Ctr Fax#: Type: Slides Block Archived Specimen: Body Site: Primary Metastatic MOLECULAR ONCOLOGY - SOLID TUMOR IHC: Global (With Interpretation) Tech-Only (Without Interpretation) FISH: Global (With Interpretation) Tech-Only (Without Interpretation) LUNG CANCER NEXT-GENERATION SEQUENCING: Driver Profile: EGFR MUTATION, ALK (FISH), ROS1 (FISH) Expanded Driver Profile: EGFR MUTATION, ALK (FISH) and ROS1 (FISH), BRAF, MET (FISH) and RET (FISH) EGFR BRAF ALK (FISH) MET (FISH) ROS1 (FISH) RET (FISH) EGFR by Peripheral Blood (Liquid Bx) EGFR M790T Drug Resistance: Solid Tumor Liquid Biopsy ALK (FISH) by Peripheral Blood (CTCs): The detection of circulating tumor cells (CTCs) in the peripheral blood followed by genetic analysis of ALK by FISH BREAST CANCER Reflex to HER2 (FISH) if HER2 (IHC) is: 0 1+ 2+ 3+ HER2/neu (FISH) Ki-67 (IHC) HER2/neu (IHC) PTEN (IHC) ER (IHC) PIK3CA (Molecular) PR (IHC) HER2 (FISH): by (CTCs) ONCOCEE-BR TM PROSIGNA: Breast Cancer Gene Assay The Prosigna Breast Cancer Prognostic Gene COLON CANCER Colon Profile: KRAS, BRAF, NRAS, PIK3CA KRAS (exons 2, 3 and 4) BRAF NRAS (exons 2, 3 and 4) PIK3CA LYNCH SYNDROME/HNPCC MMR (IHC) (MLH1, MSH2, MSH6, PMS2) Reflex to MSI (PCR) when MMR intact If loss of MLH1 by IHC reflex to MLH1 - Methylation (MethylTek TM ) - GoPath s proprietary, quantitative methylation-specific PCR assay BRAF reflex to MLH1 - Methylation (MethylTek TM ) Microsatellite Instability (MSI) ONCODEFENDER TM -CRC OncoDefender TM OncoDefender TM -CRC is a molecular test that can predict risk of recurrence for early stage colorectal cancer (Stage I/II) GASTRIC CANCER HER2/neu (IHC) Reflex to HER2 (FISH) if HER2 (IHC) is: 0 1+ 2+ 3+ HER2/neu (FISH) DISTAL ESOPHAGEAL CANCER HER2/neu (IHC) Signature Assay is an in vitro diagnostic assay that is performed on the NanoString ncounter Reflex to HER2 (FISH) if HER2 (IHC) is: DX Analysis System using FFPE breast tumor tissue previously diagnosed as invasive breast 0 1+ 2+ 3+ carcinoma. (Send out) HER2/neu (FISH) Special Instructions / Add On Tests / Stand Alone / Other Tumor Types: A signature certifies that he/she is licensed to order the test(s) listed above and that tests ordered are necessary for the treatment of the above patient. ONCOTARGET TM - 88 Robust and powerful hybrid capture NGS panel detecting mutations, rearrangements, copy number and MSI THYROID CANCER Digital Thyroid Profile BRAF, KRAS, NRAS (Sensitivity is 0.1%) BRAF NRAS Thyroid FISH RET KRAS MELANOMA CANCER Melanoma Profi le: BRAF, NRAS, ckit BRAF NRAS ckit GIST GIST Profile: ckit (for GIST tumors), PDGFR, BRAF ckit (for GIST tumors) PDGFR BRAF PROSTATE CANCER PTEN (FISH) PCA3 ERG (IHC) BLADDER CANCER Urine FISH (reflex on atypical urine cytology) CystoSnap TM - GoPath s proprietary, highly sensitive molecular mutational analysis for bladder cancer in the urine Urine FISH reflex to CystoSnap TM BRAIN CANCER Brain Profile: 1p/19q Deletion-FISH IDH1/IDH2, MGMT Promoter Methylation 1p/19q Deletion FISH IDH1/IDH2 MGMT Promoter Methylation OVARIAN CANCER BRAF KRAS PIK3CA TUMOR OF UNKNOWN PRIMARY Cancer Type ID (Send out) Preparing Samples (Solid Tumor) FFPE tissue blocks are preferred. Blanks at 4 µm for 10 slides or at 8 µm for 5 slides are acceptable when blocks cannot be provided. Specimen types include: endoscopic biopsies, excisional biopsies, core needle biopsies, surgical resections and cell blocks (pleural effusions, ascites). Use GoPath Labs kit for transport. Ship at room temperature. Include copy of this requisition. Authorized Signature Date: To view reports, please visit www.gopathlabs.com and click Online Reporting ONCOTARGET TM - 48 48 actionable hotspot genes detected GP-10-02-0417 Our requisition is easy-to-read with clearly-defined categories listed by cancer type, which makes for easy test ordering. All of our requisitions are also available online and can be customized with your office s information to streamline the ordering process. OncoTarget Specimen Requirements Preparation of normal and tumor genomic DNA can be extracted from FFPE block, or alternately, from saliva or blood for matched normal. The DNA is subsequently subjected to quantification, DNA fragmentation and library preparation procedures. Table 5 describes the collection amount required for OncoTarget - 88 testing. GoPath Laboratories will provide the corresponding DNA collection kit depending on the collection sample. Table 5. OncoTarget - 88 Samples Required Specimen Tumor Tissue FFPE Non-Tumor Tissue FFPE Saliva, Blood Shipping Conditions Quantity 10-15 5 µm blanks 10-15 5 µm blanks For matched normal, as specified Room temperature for FFPE; Cold pad for saliva or blood GoPath Connect TM : Stay Connected to Your Patients Reports 24/7 GoPath Connect TM makes it easy to connect to your patients pathology reports anytime, from anywhere. With a wide range of test ordering and result retrieval options, as well as cloud-based solutions, GoPath Connect TM works seamlessly with your existing platform and workflow and connects you with your patient s reports and images in real-time from any device that is connected to the internet. Virtual pathology resources All data accessible from our website View high quality images Email/fax report notification Safe, encrypted data environment One-click report printing Optional remote auto-faxing Web-based & paper ordering Time-saving & secure e-requisitions EMR/PMS interfacing GoPath Laboratories - 5

GoPath Laboratories Client Services Let Us Help You Get Started Providing appropriate information saves valuable time, eliminates confusion, limits phone calls & shortens turnaround time. Indicate Billing Patient s Legal Name Patient s DOB and Gender Date of Service / Collection Patient s Address and Phone Number Ordering Physician s Name, Facility and NPI ICD10-CM Codes Account Set Ups Immediate Customized Requisitions Personalized In-Service and Training Convenient Supply Ordering Specialized Account Set Up Team Office Pickup Options Local Courier Services FedEx Express FedEx Same Day City Billing Capabilities Billing shouldn t frustrate your patients or distract your staff. We offer the following billing solutions: In-Network Lab Accepting All Government Insurances Work With Most Insurances & Customized Billing Options Available Convenient Client Billing Dedicated Billing Support Technical and Professional Model Billing also Available Tech-Only Services Visit Us at GoPathLabs.com and Get Access to: List of All Tests Offered Requisitions Current Services Provided Research Collaborations Licenses and Accreditations FISH/IHC/LIS Reporting Test Supply Order Forms Information About Our Pathologists, Scientific and Executive Team Members GoPath Laboratories, LLC 1351 Barclay Blvd., Buffalo Grove, IL 60089 Toll Free: 1-855-GOPATH9 (855-467-2849) Fax: 224-588-9941 E-Mail: sales@gopathlabs.com www.gopathlabs.com